[go: up one dir, main page]

MX2016002479A - Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. - Google Patents

Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.

Info

Publication number
MX2016002479A
MX2016002479A MX2016002479A MX2016002479A MX2016002479A MX 2016002479 A MX2016002479 A MX 2016002479A MX 2016002479 A MX2016002479 A MX 2016002479A MX 2016002479 A MX2016002479 A MX 2016002479A MX 2016002479 A MX2016002479 A MX 2016002479A
Authority
MX
Mexico
Prior art keywords
acetyl
coa carboxylase
acne vulgaris
treating acne
carboxylase inhibitors
Prior art date
Application number
MX2016002479A
Other languages
English (en)
Inventor
William Paul Esler
Gabriele Elisabeth Sonnenberg
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016002479A publication Critical patent/MX2016002479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se relaciona con métodos para tratar y/o prevenir el acné en pacientes, que comprende la etapa de administrar a pacientes en necesidad de tal tratamiento, una cantidad terapéuticamente efectiva de un inhibidor ACC o una sal farmacéuticamente aceptable del mismo.
MX2016002479A 2013-09-12 2014-08-29 Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. MX2016002479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877058P 2013-09-12 2013-09-12
PCT/IB2014/064151 WO2015036892A1 (en) 2013-09-12 2014-08-29 Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

Publications (1)

Publication Number Publication Date
MX2016002479A true MX2016002479A (es) 2016-05-31

Family

ID=51541122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002479A MX2016002479A (es) 2013-09-12 2014-08-29 Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.

Country Status (17)

Country Link
US (1) US20160220557A1 (es)
EP (1) EP3043800A1 (es)
JP (1) JP2016534091A (es)
KR (1) KR20160042089A (es)
CN (1) CN105530940A (es)
AR (1) AR097619A1 (es)
AU (1) AU2014319990A1 (es)
BR (1) BR112016004118A2 (es)
CA (1) CA2923884A1 (es)
HK (1) HK1217448A1 (es)
IL (1) IL243969A0 (es)
MX (1) MX2016002479A (es)
RU (1) RU2016106829A (es)
SG (1) SG11201600711PA (es)
TW (1) TW201521722A (es)
WO (1) WO2015036892A1 (es)
ZA (1) ZA201601084B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
AU2018291163B2 (en) 2017-06-30 2024-07-18 Quixgen, Inc. Novel spirolactone compounds
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
GB201812561D0 (en) 2018-08-01 2018-09-12 Univ Manchester Biomarkers and uses thereof
WO2020245297A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
WO2020245291A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
EP4014964A1 (en) 2020-12-21 2022-06-22 Almirall S.A. Topical formulation
US20250041279A1 (en) 2021-11-19 2025-02-06 Shionogi & Co., Ltd. Therapeutic medicine for heart disease or skeletal muscle disease
CA3263179A1 (en) * 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855897A (en) * 1996-09-13 1999-01-05 E-L Management Corp. Topical composition and method for enhancing lipid barrier synthesis
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
JPH11171847A (ja) 1997-09-26 1999-06-29 Fujirebio Inc ブタン酸アミド誘導体
US6120756A (en) * 1998-08-19 2000-09-19 Philip I. Markowitz Topical anionic salicylate for disorders of the skin
KR20020060737A (ko) 1999-11-12 2002-07-18 추후보정 암세포를 선택적으로 사멸시키기 위한 수단으로서의세포내 조효소 ａ 농도의 감소 방법
AR036492A1 (es) * 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
JP2005194191A (ja) 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US6485941B1 (en) 2002-04-23 2002-11-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies
US7211423B2 (en) 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
US20060178400A1 (en) 2004-11-05 2006-08-10 Beutel Bruce A Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8299041B2 (en) 2005-04-08 2012-10-30 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
JP2007161630A (ja) * 2005-12-13 2007-06-28 Adeka Corp 皮脂抑制剤
WO2007095602A2 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007095601A2 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
JPWO2007119833A1 (ja) 2006-04-14 2009-08-27 武田薬品工業株式会社 含窒素複素環化合物
CA2668414C (en) * 2006-11-03 2015-02-10 Qlt Inc. Methods of treating dermatological disorders or conditions
KR20080052024A (ko) 2006-12-07 2008-06-11 (주)아모레퍼시픽 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
WO2008079610A2 (en) 2006-12-21 2008-07-03 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2128163A1 (en) 2007-01-25 2009-12-02 Takeda Pharmaceutical Company Limited Spiro-ring compound
EP2123652A1 (en) 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20090005375A1 (en) 2007-03-30 2009-01-01 Edcon Chang Acetyl coenzyme a carboxylase inhibitors
CN101795701A (zh) 2007-05-14 2010-08-04 纽尔雅制药公司 用于治疗神经元代谢减退的乙酰coa羧化酶抑制剂
CA2687964A1 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20090155815A1 (en) 2007-10-26 2009-06-18 Grasberger Bruce L Crystal structure of the carboxyl transferase domain of human acetyl-coa carboxylase 2 protein (acc2 ct) and uses thereof
JP2009196966A (ja) 2008-02-25 2009-09-03 Takeda Chem Ind Ltd ピラゾリジンジオン誘導体
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
AU2009266730B2 (en) 2008-07-04 2013-07-18 Msd K.K. Novel spirochromanone carboxylic acids
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2011005660A1 (en) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Tofa analogs useful in treating dermatological disorders or conditions
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
CN101876925B (zh) 2009-11-27 2012-05-02 成都市华为赛门铁克科技有限公司 内存镜像处理方法、装置和系统
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008642A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008643A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
JP2011225455A (ja) 2010-04-15 2011-11-10 Kao Corp Ｓｒｅｂｐ抑制剤
TW201206911A (en) 2010-04-27 2012-02-16 Takeda Pharmaceutical Bicyclic compound
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20120129833A1 (en) 2010-08-20 2012-05-24 Bayer Pharma Aktiengesellschaft Cyclic ketoenols for therapy
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
HUE025078T2 (en) 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
CA2819400A1 (en) 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
AP2013007057A0 (en) 2011-02-06 2013-08-31 Bayer Ip Gmbh (5S,8S)-3-(4'chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one(compound A)for treatment
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物
SG194142A1 (en) * 2011-04-22 2013-11-29 Pfizer Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
US8844103B2 (en) 2011-09-01 2014-09-30 Medtronic, Inc. Methods for making feedthrough assemblies including a capacitive filter array
US20150246938A1 (en) 2011-09-09 2015-09-03 Shionogi & Co., Ltd. Novel olefin derivative
WO2013061962A1 (ja) 2011-10-24 2013-05-02 武田薬品工業株式会社 二環性化合物
UA123760C2 (uk) 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
JP6129199B2 (ja) 2011-12-02 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
US8765959B2 (en) 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
US8530461B2 (en) * 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
HK1217448A1 (zh) 2017-01-13
RU2016106829A (ru) 2017-10-17
TW201521722A (zh) 2015-06-16
EP3043800A1 (en) 2016-07-20
CA2923884A1 (en) 2015-03-19
CN105530940A (zh) 2016-04-27
SG11201600711PA (en) 2016-03-30
US20160220557A1 (en) 2016-08-04
ZA201601084B (en) 2017-05-31
KR20160042089A (ko) 2016-04-18
JP2016534091A (ja) 2016-11-04
AU2014319990A1 (en) 2016-02-25
BR112016004118A2 (pt) 2017-10-17
WO2015036892A1 (en) 2015-03-19
AR097619A1 (es) 2016-04-06
IL243969A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
ZA201700572B (en) Therapeutically active compounds and their methods of use
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
PH12016500768A1 (en) Methods of treating and preventing graft versus host disease
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1227288A1 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma